BOOK REVIEW: Leukemia

Publication
Article
OncologyONCOLOGY Vol 10 No 9
Volume 10
Issue 9

This text, originally published as Dameshek and Gunz's textbook Leukemia (1958), is now edited by an international team consisting of Dr. Henderson, Dr. Lister, and Dr. Greaves. This continues to be an outstanding text in its field, covering virtually all aspects of the acute and chronic leukemias.

This text, originally published as Dameshek and Gunz's textbookLeukemia (1958), is now edited by an international teamconsisting of Dr. Henderson, Dr. Lister, and Dr. Greaves. Thiscontinues to be an outstanding text in its field, covering virtuallyall aspects of the acute and chronic leukemias.

Written for the most part for the practicing oncologist, the bookis well organized, with a well-placed emphasis on the scientificand epidemiologic aspects of these diseases. The chapter on chemicalsand leukemia provides an exceptionally good review of this particulartopic.

As noted by Mel Greaves in his chapter, "The New Biologyof Leukemia," the degree of molecular diversity in thesediseases is just beginning to be understood. With this in mind,it is somewhat disappointing to note, in this otherwise robusttext, some thin areas that deal with important molecular discoveries.Specifically, the role of differentiation therapy with retinoidsin the treatment of acute promeylocytic leukemia and its relationshipto t(15;17) is given only a few paragraphs; this is indeed shortshrift for one of the most intriguing discoveries made in thetreatment of acute leukemia. A more comprehensive descriptionof t(9;22) also should be provided. Similarly, the role of interferon-alfain chronic myelegenous leukemia is only briefly reviewed, eventhough this is perhaps one of the few advances that has been madein this disease, albeit for only a proportion of patients.

Despite these few deficiencies, however, Leukemia remainsan excellent reference source on these malignancies.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Related Content